Pancreatic Cancer: Medical Treatments

Department of Health written question – answered on 7th January 2016.

Alert me about debates like this

Photo of Karin Smyth Karin Smyth Labour, Bristol South

To ask the Secretary of State for Health, when his Department plans to make a decision on whether to refer for consideration by NICE PRRNT treatment for pancreatic cancers.

Photo of George Freeman George Freeman The Parliamentary Under-Secretary of State for Business, Innovation and Skills, The Parliamentary Under-Secretary of State for Health

The National Institute for Health and Care Excellence (NICE) has recently consulted stakeholders on the suitability of Lutetium-177 Dotatate - a type of peptide receptor radionuclide therapy (PRRT) - for treating unresectable, somatostatin receptor-positive gastroentero-pancreatic neuroendocrine tumours without disease progression for referral to its technology appraisal work programme. A decision on its referral to NICE will be taken shortly.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.